RESUMO
BACKGROUND: Rifampicin (RIF) is considered the backbone of TB treatment, but adverse effects often limit its use. METHODS: This retrospective cohort study examined patients treated for TB disease at our institution, and compared those who received RIF to those who were intolerant to RIF. RESULTS: A total of 829 patients were included. Seventy-six patients (9%) were intolerant to RIF. Patients with RIF intolerance were significantly older (median age: 67 years, IQR 50-78 vs. 48 years, IQR 31-70; P < 0.0001), and were more likely to be female (57% vs. 41%; P = 0.01) and have concurrent diabetes mellitus (37.3% vs. 19%; P < 0.0001) compared to those who tolerated RIF. RIF intolerance was most commonly due to transaminitis (25%), cytopenia (14.5%), rash (17.1%) and gastro-intestinal intolerance (7.8%). Twenty patients were subsequently challenged with rifabutin, and this was successful in 70%. The mean treatment duration was significantly longer in patients who were intolerant to RIF (335 vs. 270 days; P < 0.001). There was no significant difference in treatment outcomes. CONCLUSION: RIF intolerance is more common in older patients, females, and those with concurrent diabetes mellitus. Patients who could not tolerate RIF had a longer duration of therapy, but no difference in treatment outcomes. When attempted, rifabutin was well tolerated in most patients with a previous RIF-related adverse event.
CONTEXTE: La rifampicine (RIF) est généralement considérée comme le pilier du traitement de la TB, cependant, ses effets indésirables limitent fréquemment son utilisation. MÉTHODES: Dans cette étude de cohorte rétrospective nous avons examiné les patients traités pour la TB dans notre institution et avons comparé ceux qui ont reçu la RIF à ceux qui n'ont pas pu la tolérer. RÉSULTATS: Au total, 829 patients ont été inclus. Soixante-seize patients (9%) étaient intolérants au RIF. Les patients intolérants au RIF étaient significativement plus âgés (âge médian : 67 ans, IQR 5078 vs. 48 ans, IQR 3170 ; P < 0,0001), et étaient plus susceptibles d'être des femmes (57% vs. 41% ; P = 0,01) et d'avoir un diabète sucré concomitant (37,3% vs. 19% ; P < 0,0001) par rapport à ceux qui toléraient le RIF. L'intolérance au RIF était principalement due à une transaminite (25%), une cytopénie (14,5%), une éruption cutanée (17,1%) et une intolérance gastro-intestinale (7,8%). Vingt patients ont ensuite été soumis à un test de provocation à la rifabutine, avec un taux de succès de 70%. La durée moyenne du traitement était significativement plus longue chez les patients intolérants au RIF (335 vs. 270 jours ; P < 0.001). Aucune différence significative n'a été observée dans les résultats du traitement. CONCLUSION: L'intolérance au RIF est plus courante chez les patients plus âgés, les femmes et les patients atteints de diabète sucré. Les patients qui n'ont pas pu tolérer le RIF ont suivi un traitement plus long, mais cela n'a pas entrainé de différence dans les résultats du traitement. Lorsqu'elle a été tentée, la rifabutine a été bien tolérée par la plupart des patients ayant déjà présenté un effet indésirable lié au RIF.
Assuntos
Transplante de Rim/estatística & dados numéricos , Doadores de Tecidos/provisão & distribuição , Obtenção de Tecidos e Órgãos/organização & administração , Algoritmos , Geografia , Alocação de Recursos para a Atenção à Saúde/métodos , Humanos , Transplante de Rim/imunologia , New England , Fatores de Tempo , Doadores de Tecidos/estatística & dados numéricos , Obtenção de Tecidos e Órgãos/métodos , Listas de EsperaRESUMO
BACKGROUND: A novel plan of renal allograft allocation has been conducted by United Network for Organ Sharing Region 1 transplant centers since September 3, 1996, based upon HLA matching, time waiting, and population distance points. The objectives of this plan were to achieve a balance between increasing the opportunity of renal transplantation for those patients listed with long waiting times and promoting local organ donor availability. METHODS: A single list of candidates was formulated for each cadaver donor, assigning a maximum of 8 points for time waiting, a maximum of 8 points for population distance from the donor hospital, and HLA points based upon the degree of B/DR mismatch. Additional points were awarded to a cross-match-negative patient with a panel-reactive antibody of >80%, and to pediatric patients. RESULTS: The total number of kidneys transplanted to patients who had waited >3 years was 100 (46%), and to patients who had waited >2.5-3 years was 29 (13%). However, the total number of kidneys transplanted to patients with the maximum population distance points was only 72 (33%). Thus, although the plan achieved a favorable distribution of kidneys to patients with longer waiting times (nearly 60%), the other, equally important objective of promoting local donor availability was not initially accomplished. Moreover, minor HLA B/DR differences between the donor and the recipient (i.e., not phenotypically matched) were unexpectedly consequential in determining allocation. As a result of these observations, the following adjustments were made in the plan (as of December 3, 1997): a maximum of 10 points for population distance, a maximum of 8 points for time waiting (both by a linear correlation), and the retention of HLA points for 0 B/DR mismatch only. After these interval changes, the percentage of patients receiving a kidney with some population distance points increased from 85% to 96%. Conclusions. We have shown that a heterogeneous region of multiple transplant centers can devise (and modify) an innovative and balanced plan that provides an equitable system of allocation for an ever-increasing number of patients.
Assuntos
Transplante de Rim , Doadores de Tecidos , Obtenção de Tecidos e Órgãos/organização & administração , Adolescente , Adulto , Cadáver , Criança , Teste de Histocompatibilidade , Humanos , Rim , Transplante de Rim/fisiologia , Transplante de Rim/estatística & dados numéricos , Preservação de Órgãos/métodos , Fatores de Tempo , Estados Unidos , Listas de EsperaRESUMO
BACKGROUND: We report the consequences of a novel kidney allocation system on access of non-Caucasians (NC) to kidney transplantation. This new plan has provided a balance of allocation determinants between time waiting, HLA match, and geography (population density between donor and recipient center). METHODS: Three sequential systems of regional allocation were analyzed: period I (September 1994 to September 1996), period II (September 1996 to November 1997), and period III (December 1997 to March 1 1999). Periods II and III are reflective of the new allocation plan. RESULTS: During periods II and III, the NC rate of kidney transplantation increased closer to the NC proportion on the wait list, comparatively exceeding the national UNOS data. There was no statistical difference in regional mean wait time between Caucasian and NC. Improvements in access to transplantation for NCs between period I and periods II and III appear to be related to changes in geographic allocation weight from local unit to population density points, to the inclusion of the entire region in the plan, and to the deletion of intermediate degrees of B/DR mismatching in the revised plan. Despite the increased proportion of NCs on the wait list from period I to period III, the percentage difference between the proportion of NCs waiting on the list and the proportion NCs receiving a transplant fell from 7.8% to 4.9%. CONCLUSIONS: These data demonstrate that this new allocation plan was associated with improved access of minority candidates to transplantation. The broadening of geographic allocation and the alteration of HLA points appear to permit a more favorable opportunity for renal transplantation to NC candidates. selection, compared to the UNOS formula. In this report, we analyze the consequences of the Region 1 allocation system on the access of non-Caucasian (NC) candidates to cadaver donor kidney transplantation.
Assuntos
Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Transplante de Rim , Grupos Minoritários , Obtenção de Tecidos e Órgãos , Humanos , Listas de Espera , População BrancaAssuntos
Tipagem e Reações Cruzadas Sanguíneas/métodos , Anticoagulantes/farmacologia , Atitude do Pessoal de Saúde , Automação , Bancos de Sangue/normas , Tipagem e Reações Cruzadas Sanguíneas/economia , Tipagem e Reações Cruzadas Sanguíneas/instrumentação , Simulação por Computador , Humanos , Laboratórios Hospitalares/economia , Sistemas Homem-Máquina , Programas de Rastreamento , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Recursos HumanosRESUMO
The tumorigenic activities of benzo[a]pyrene (BP) and 6-fluorobenzo[a]pyrene (6-F-BP) were compared to determine whether an unsubstituted 6-position is important for the carcinogenic effect of BP. Highly purified samples of 6-F-BP and BP had similar activities for the induction of lung adenomas in Swiss Webster mice treated before weaning. The 6-fluoro derivative, however, had about one-half as much activity as BP for the initiation of skin papillomas in CD-1 mice. Similarly, 6-F-BP (approximately equal to 90% purity) had about one-half the activity of BP for the induction of skin tumors in C57BL/6J mice given repetitive treatments of the hydrocarbons and for the induction of sarcomas in C3H/fCum mice given a single sc injection. 6-F-BP (approximately equal to 90% purity) had activity similar to that of BP for induction of sarcomas at the sc injection site in Fischer 344 rats. These results and related data indicate the need for detailed metabolic studies whenever fluorine substitution is used as a probe to assess the role of the unsubstituted position in the carcinogenicity of the parent compound.
Assuntos
Benzopirenos/toxicidade , Carcinógenos/toxicidade , Neoplasias Hepáticas Experimentais/induzido quimicamente , Neoplasias Pulmonares/induzido quimicamente , Papiloma/induzido quimicamente , Sarcoma Experimental/induzido quimicamente , Neoplasias Cutâneas/induzido quimicamente , Animais , Benzo(a)pireno , Feminino , Neoplasias Hepáticas Experimentais/patologia , Neoplasias Pulmonares/patologia , Masculino , Camundongos , Neoplasias Experimentais/patologia , Papiloma/patologia , Ratos , Sarcoma Experimental/patologia , Fatores Sexuais , Neoplasias Cutâneas/patologia , Especificidade da EspécieAssuntos
Benzopirenos/toxicidade , Di-Hidroxi-Di-Hidrobenzopirenos , Fibrossarcoma/induzido quimicamente , 7,8-Di-Hidro-7,8-Di-Hidroxibenzo(a)pireno 9,10-óxido , Animais , Benzopirenos/metabolismo , Biotransformação , Avaliação Pré-Clínica de Medicamentos , Compostos de Epóxi/metabolismo , Compostos de Epóxi/toxicidade , Masculino , Camundongos , Camundongos Endogâmicos C3H , Sarcoma Experimental/induzido quimicamente , Relação Estrutura-AtividadeAssuntos
Carcinógenos , Crisenos/toxicidade , Compostos de Epóxi/toxicidade , Éteres Cíclicos/toxicidade , Mutagênicos , Fenantrenos/toxicidade , Animais , Crisenos/metabolismo , Cricetinae , Epóxido Hidrolases/metabolismo , Feminino , Técnicas In Vitro , Masculino , Camundongos , Neoplasias Experimentais/induzido quimicamente , Fenantrenos/metabolismo , Ratos , Salmonella typhimurium/efeitos dos fármacos , Neoplasias Cutâneas/induzido quimicamente , Relação Estrutura-AtividadeRESUMO
In order to study the biological effects of (+)- and (-)-benzo[a]pyrene 4,5-oxide, a synthesis of these molecules has been developed based on the resolution of (+/-)-cis-4,5-dihydroxy-4,5-dihydrobenzo[a]pyrene. The (-) enantiomer of benzo[a]pyrene 4,5-oxide was 1.5- to 5.5-fold more mutagenic than the (+) enantiomer in strains TA 98, TA 100, TA 1537, and TA 1538 of Salmonella typhimurium and in Chinese hamster V79 cells. In studies with V79 Cells, the (-) enantiomer of benzo[a]pyrene 4,5-oxide was also more cytotoxic than the (+) enantiomer. When mixtures of the enantiomers were studied in V79 cells, synergistic cytotoxic and mutagenic responses were observed. The greatest cytotoxic and mutagenic effects occurred with a 3:1 mixture of the (-) and (+) enantiomers of benzo[a]pyrene 4,5-oxide, respectively.
Assuntos
Benzopirenos/farmacologia , Citotoxinas , Mutagênicos , Animais , Linhagem Celular , Cricetinae , Sinergismo Farmacológico , Compostos de Epóxi , Isomerismo , Salmonella typhimurium/efeitos dos fármacos , Relação Estrutura-AtividadeRESUMO
Benzo(a)pyrene (BP), 2-hydroxybenzo(a)pyrene (2-HOBP), and 6-hydroxybenzo(a)pyrene (6-HOBP) were tested for tumorigenicity by i.p. injection into newborn mice. The mice were treated sequentially with 200, 400, and 800 nmol of compound on the first, eighth and fifteenth day of life, and the animals were killed at 24 weeks of age. Treatment with 2-HOBP caused about 4-fold more pulmonary tumors than BP, while 6-HOBP had little or no tumorigenic activity. Newborn mice treated with 2-HOBP, BP, and 6-HOBP had a 98, 81, and 11% incidence of pulmonary adenomas with an average of 24, 6.4, and 0.11 adenomas per mouse, respectively. In the control group, 7.5% of the animals had pulmonary adenomas with an average of 0.08 adenoma per mouse. When 25, 50, or 100 nmol of BP or 2-HOBP was applied to mouse skin once every 2 weeks for 60 weeks, both compounds had about the same carcinogenic activity. These results demonstrate the importance of evaluating the carcinogenic potential of chemicals in more than one tumor system. BP and 2-HOBP were tested for mutagenicity towards two strains of Salmonella typhimurium and towards Chinese hamster V79 cells in the presence of hepatic microsomes from rats pretreated with Aroclor 1254. The products formed during the metabolism of 2-HOBP or BP by liver microsomes had significant mutagenic activity.
Assuntos
Adenoma/induzido quimicamente , Animais Recém-Nascidos , Benzopirenos/toxicidade , Carcinógenos , Neoplasias Pulmonares/induzido quimicamente , Animais , Células Cultivadas , Cricetinae , Cricetulus , Injeções Intraperitoneais , Camundongos , Camundongos Endogâmicos C57BL , Mutagênicos , Neoplasias Experimentais/induzido quimicamente , Salmonella typhimurium/efeitos dos fármacos , Pele/efeitos dos fármacos , Neoplasias Cutâneas/induzido quimicamenteRESUMO
The tumor-initiating activities of chrysene and the three metabolically possible trans-dihydrodiols at the 1,2-, 3,4-, and 5,6-positions of chyrsene were determined on the skin of female CD-1 mice. A single topical application of 0.4, 1.25, or 4.0 mumol of each compound was followed 7 days later by twice-weekly applications of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate for 25 weeks. The most potent tumor initiator was chrysene 1,2-dihydrodiol, which had approximately twice the tumorigenic activity of the parent hydrocarbon chrysene at all doses tested. Chrysene 3,4-dihydrodiol and chrysene 5,6-dihydrodiol had no significant tumorigenic activity. 1,2-Dihydroxy-1,2,3,4-tetrahydrochrysene, a compound related to chrysene 1,2-dihydrodiol but with the conjugated nonaromatic double bond removed from the 3,4-position of the molecule, had less than 25% of the tumorigenic activity of chrysene 1,2-dihydrodiol. These results indicate that chrysene 1,2-dihydrodiol is a proximate carcinogenic metabolite of chrysene and that a chrysene 1,2-diol-3,4-epoxide, in which the epoxide group forms part of the bay region in the molecule, is a likely candidate as an ultimate carcinogenic metabolite of chrysene.
Assuntos
Carcinógenos , Crisenos/metabolismo , Fenantrenos/metabolismo , Neoplasias Cutâneas/induzido quimicamente , Animais , Fenômenos Químicos , Química , Crisenos/toxicidade , Feminino , Camundongos , Neoplasias Experimentais/induzido quimicamenteAssuntos
Benzopirenos/metabolismo , Mutagênicos/metabolismo , Animais , Benzopirenos/síntese química , Benzopirenos/farmacologia , Epóxido Hidrolases/metabolismo , Microssomos Hepáticos/enzimologia , Ratos , Salmonella typhimurium/efeitos dos fármacos , Estereoisomerismo , Relação Estrutura-AtividadeAssuntos
Crisenos/farmacologia , Microssomos Hepáticos/metabolismo , Mutagênicos , Fenantrenos/farmacologia , Salmonella typhimurium/genética , Animais , Fenômenos Químicos , Química , Sistema Enzimático do Citocromo P-450/farmacologia , Relação Dose-Resposta a Droga , Compostos de Epóxi/farmacologia , Masculino , Oxigenases/metabolismo , Ratos , Relação Estrutura-AtividadeAssuntos
Benzopirenos/toxicidade , Neoplasias Cutâneas/induzido quimicamente , Animais , Benzopirenos/metabolismo , Carcinoma de Células Escamosas/induzido quimicamente , Feminino , Isomerismo , Camundongos , Camundongos Endogâmicos C57BL , Neoplasias Experimentais/induzido quimicamente , Fenóis/toxicidade , Relação Estrutura-AtividadeAssuntos
Adenosina/farmacologia , Química Encefálica/efeitos dos fármacos , AMP Cíclico/biossíntese , Adenosina/análogos & derivados , Adenosina/antagonistas & inibidores , Trifosfato de Adenosina/farmacologia , Animais , AMP Cíclico/farmacologia , Cobaias , Técnicas In Vitro , Relação Estrutura-Atividade , Xantinas/farmacologiaRESUMO
A variety of radioactive analogs of adenine and adenosine were incubated with guinea pig cerebral cortical slices. Neither 1,N6-etheno[14C] adenosine nor 1,N6-etheno[14C] adenine were significantly incorporated into intracellular nucleotides. 2-chloro[8-3H] adenine was incorporated, but at a very low rate and conclusive evidence for the formation of intracellular radioactive 2-chloro-cyclic AMP was not obtained. N6-Benzyl[14C] adenosine was converted only to intracellular monophosphates and significant formation of radioactive N6-benzylcyclic AMP was not detected during a subsequent incubation. 2'-Deoxy-[8-14C] adenosine was converted to both intracellular radioactive 2'-deoxy-adenine nucleotides and radioactive adenine nucleotides. Stimulation of these labeled slices with a variety of agents resulted in formation of both radioactive 2'-deoxycyclic AMP and cyclic AMP. Investigation of the effect of various other compounds on uptake of adenine or adenosine suggested that certain other adenosine analogs might serve as precursors of abnormal cyclic nucleotides in intact cells.